Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
33%
Ph phase_1
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 2Efficacy & side effects
1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Completed(1)

Detailed Status

Recruiting1
Completed1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (50.0%)
Phase 21 (50.0%)

Trials by Status

recruiting133%
completed133%
not_yet_recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
not_yet_recruitingphase_2

Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer

NCT06943664
recruitingphase_1

Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction

NCT06306638
completed

Feasibility of Mobile-CT-Assisted Bronchoscopy for the Diagnosis of Lung Lesion

NCT04995172

Clinical Trials (3)

Showing 3 of 3 trials
NCT06943664Phase 2

Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer

Not Yet Recruiting
NCT06306638Phase 1

Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction

Recruiting
NCT04995172

Feasibility of Mobile-CT-Assisted Bronchoscopy for the Diagnosis of Lung Lesion

Completed

All 3 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
3